Covidien Unlimited Co.

SAN MATEO, Calif.--( BUSINESS WIRE )--Presidio Medical, Inc., a clinical stage company developing a transformational neuromodulation platform, is pleased to announce Richard J. Buchholz will join its Board of Directors. Rick is the Chief Financial Officer of Inspire Medical Systems, Inc. (NYSE: INSP), where he has played a pivotal role in driving strategic financial and operational growth for the global leader in the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. “We are excited that Rick is joining the Board of Directors of Presidio Medical at this critical time in our company’s journey. His leadership and financial acumen will be instrumental in advancing our vision through key growth and development stages,” said Michael Onuscheck, Chairman and CEO of Presidio Medical. “I am excited to join the Board as an independent Director and work with the entire team through the next phases of the company’s development,” said Mr. Buchholz. “Presidio Medical’s vision of revolutionizing the way neuromodulation balances the human nervous system – enabling people to live their best life, aligns with my passion for bringing innovative technologies to market that could profoundly impact patient care.” Since 2014, Mr. Buchholz has served as the Chief Financial Officer of Inspire Medical Systems, Inc. Prior to joining Inspire, Mr. Buchholz served as the Chief Financial Officer at superDimension, Ltd. from 2006 through its acquisition by Covidien plc in 2013. Mr. Buchholz also served as the Chief Financial Officer of Vascular Solutions, Inc., which was acquired by Teleflex Incorporated. Mr. Buchholz holds a B.B.A. from the University of Wisconsin, Eau Claire and is a Certified Public Accountant (inactive). Rick’s appointment to the Board of Directors reflects Presidio Medical’s commitment to attracting top-tier leadership to drive its strategic objectives and accelerate the adoption of its innovative solutions in healthcare. About Presidio Medical Presidio Medical was founded in 2017 and is headquartered in San Mateo, CA. The clinical stage privately held medical device company is developing a transformational neuromodulation platform to treat diseases of undesired neural activity with a first indication in the treatment of chronic pain. Presidio’s investors include Deerfield Management, Invus Opportunities, Action Potential Venture Capital, and ShangBay Capital. For more information, visit www.presidiomedical.com .

LUXEMBOURG & NEW YORK & LONDON & PARIS--( BUSINESS WIRE )--Astorg, a leading pan-European private equity firm, is pleased to announce the completion of its take-private of Hamilton Thorne, and simultaneous acquisition of Cook Medical’s Reproductive Health business (“Cook Medical RH”). Cook Medical RH brings a leading portfolio of ART consumables and equipment including ovum aspiration needles, catheters, and pipettes. Hamilton Thorne brings a leading ART portfolio of precision instruments, consumables, software, and services. Upon closing of the transactions, Hamilton Thorne is delisted from the Toronto Stock Exchange. Astorg is now bringing the two businesses together to create a new global ART MedTech company. A new brand identity for the combined business will be rolled out in 2025. The combined business will serve customers in over 115 countries offering fertility clinics and IVF laboratories a comprehensive portfolio of high-quality and innovative products improving the outcomes and accessibility of fertility treatments globally. “By the joining of forces of Hamilton Thorne and Cook Medical RH we are creating a unique, global, pure-play ART business at scale, with market leadership and an industry-leading product portfolio that is ideally positioned to address rising fertility challenges and better support fertility professionals and families on their fertility journeys,” said Olivier Lieven , Managing Director, Astorg . “The Astorg Healthcare team will continue to leverage its strong track record in specialized MedTech and carve-out expertise to build a global leader in ART. We look forward to driving this next stage of growth, partnering closely with the combined business.” To lead the combined global business into its next phase of growth, a new management team has been appointed. Astorg, together with the new management team and all employees across the combined business, will support the delivery of high quality, value-added, and innovative products and services to fertility clinics and IVF laboratories globally. Wil Boren has been appointed as Chief Executive Officer (“CEO”), bringing decades of experience in the MedTech sector and who has proven to be an accomplished leader. He most recently served as CEO of Paragon Medical, a carve-out from NN, where he unified 17 manufacturing sites and managed nearly 3,000 employees, driving significant improvements in service delivery, performance, and revenue growth before the business’ sale to AMETEK in 2023. Prior to Paragon, Wil held several key leadership roles including President of Advanced Surgery at Baxter Healthcare, General Manager of Connected Health at Zimmer Biomet, and President of Sports, Extremities, and Trauma and President of International at Biomet. Jimmy DeStephens has been appointed as Chief Financial Officer (“CFO”) and Chief Operating Officer (“COO”), bringing over 20 years of expertise in finance, operations, and business development within the MedTech industry. He joins from Corza Medical, where, as General Manager of the Global Wound Closure business, he drove substantial growth through new go-to-market strategies and key investments across the U.S. and Europe. Jimmy has also held leadership roles at Baxter Healthcare, Acelity, Medtronic, Covidien, and Tyco. Tobias Nordblom, Managing Director, Astorg , commented: “We are delighted to welcome Wil as the new CEO of the combined business, along with Jimmy as CFO and COO. Wil’s impressive track record of leading, integrating and growing international MedTech businesses makes him uniquely positioned to lead the new company. We look forward to partnering with Wil, the leadership team and all employees across the combined business to create a global ART leader driven by innovation and supported by high quality products and a strong customer focus.” In addition, he added: “We would like to thank Dr. Kate Torchilin and Francesco Fragasso for their excellent leadership of Hamilton Thorne and their strong partnership in helping bring the two companies together.” Wil Boren, CEO , concluded: “Today marks a pivotal moment for Hamilton Thorne and Cook Medical RH and I am thrilled to lead the newly combined company, and I look forward to working with both teams joining forces. Hamilton Thorne and Cook Medical RH have impressive reputations, a broad range of innovative and quality-driven products, and outstanding customer service – a testament to the dedication and expertise of both teams. With our combined scope, expertise, and resources, we are uniquely positioned to help IVF clinics and patients, all with the goal of expanding access and improving fertility outcomes worldwide." Healthcare is one of Astorg’s core expertise with over €6.5bn invested in the sector. Astorg invests in global B2B Healthcare leaders in Europe and in the US, its most recent investments include hg Medical, CordenPharma, OPEN Health, Avania, Cytel, and Clario. This latest investment will be part of Astorg VIII portfolio, representing the seventh portfolio company of the fund to date, and the third in Healthcare. Jefferies Securities, Inc served as exclusive financial advisor to Astorg. Stikeman Elliott LLP and Weil, Gotshal & Manges LLP acted as legal advisors to Astorg. Financial terms for the Cook Medical RH transaction were not disclosed. About Astorg Astorg is a leading pan-European private equity firm with over €23 billion of assets under management. Astorg works with entrepreneurs and management teams to acquire market leading global companies headquartered in Europe or the US, providing them with the strategic guidance, governance and capital they need to achieve their growth goals. Enjoying a distinct entrepreneurial culture, a long-term shareholder perspective and a lean decision-making body, Astorg has valuable industry expertise in healthcare, software, technology, business services and technology-based industrial companies. Headquartered in Luxembourg, Astorg has offices in London, Paris, New York, Frankfurt, and Milan. For more information about Astorg: www.astorg.com | Follow Astorg on LinkedIn About Hamilton Thorne Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and the cell biology space. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, IVFtech, Embryotech Laboratories, Tek-Event, Microptic, and Gynetics brands, through its growing sales force and distributors worldwide. Hamilton Thorne customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments. For more information about Hamilton Thorne: https://www.hamiltonthorne.ltd/ About Cook Medical Since 1963, Cook Medical has worked closely with physicians to develop technologies that eliminate the need for open surgery. Today we invent, manufacture and deliver a unique portfolio of medical devices to the healthcare systems of the world. Serving patients is a privilege, and we demand the highest standards of quality, ethics and service. We have remained family owned so that we have the freedom to focus on what we care about: patients, our employees and our communities. Find out more at CookMedical.com and for the latest news, follow us on Twitter, Facebook and LinkedIn.

DUBLIN--( BUSINESS WIRE )--The "Raw Material Requirements (Health Canada/USP/EP) in a cGMP Environment - Issues and Solutions Training Course" training has been added to ResearchAndMarkets.com's offering. The World Compliance seminars team has come up with a detailed course on raw material compliance to understand the intricacy of an ingredient in a product. We have enforced the idea of good manufacturing practices through several pharmaceutical GMP training programs. However, minute elements like raw materials need critical attention to avoid warning letters. Every biotech product is an amalgam of multiple raw materials that add purpose and efficiency to it. Since raw materials are the foundation of these products, it is important to have regulatory norms in place for them. Hence, this seminar discusses raw material compliance to ensure every final product meets FDA expectations and guidelines. Course Overview Did you know more than 5000 firms received the notice for not having cGMP-controlled raw materials? This is not a scenario you dream of while running a pharmaceutical and biotech manufacturing business. As much as the cGMP course plays an essential role, concerned personnel needs to understand regulatory requirements for raw materials. The basic framework of this course is different from cGMP online training. It includes topics like testing and approval of the raw materials, rejection criteria of components, product container management, and closures. As far as the benefits of pharmaceutical cGMP training are concerned, you will learn the following things: Basic guidelines to formulate representative samples for effective testing and inspection Best practices to release each component, packaged product, and closures Appropriate techniques to collect samples alongside preventing contamination, maintaining sterility in equipment, and aseptic processing General criteria for testing and examination of the samples Impact of multiple raw materials on the end user Adhere to the best practices required for commercial-grade manufacturing In addition to these general topics, here are the topics that will be discussed in the seminar. Who Should Attend: Raw material compliance is currently the talk of the town and upskilling yourself will help you in building a positive career. Moreover, additional knowledge of cGMP violations will help you excel in the department. Below are some professionals who will benefit from this FDA compliance training: Regulatory and Compliance Professionals: Develop the ability to identify loopholes and build a better system for raw material procurement and processing. Manufacturing and Quality Engineers: Assess the quality of the product internally and set a benchmark for the entire team to avoid warning letters and product recalls. Document Control Specialists: Gain perspective on documenting the characteristics of the raw material appropriately for future reference. Quality Auditors : In-house auditors play an essential role in product examination and are responsible for giving critical feedback on the entire system. Project Managers: The course will help them understand basic regulations related to raw materials so they can take suitable action and manage product development. 12.0 RAC CREDITS RAPS - This course has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion. Speakers: Barry A. Friedman, Ph.D Consultant Cambrex Bio Sciences Dr. Friedman possesses over 30 years of industrial managerial experience in various aspects of biopharmaceuticals and medical devices to include regulatory compliance, expert witness testimony, GLP/GMP, quality control, auditing, sterility assurance, microbiological/analytical validations and fermentation technology. Prior to becoming an independent consultant, Dr. Friedman was associated with Cambrex Bio Sciences, a contract manufacturer of GMP bulk biopharmaceuticals located in Baltimore, Maryland. As the Director of Quality Control, he managed a multi-shift Department of thirty one individuals involved in client management, the receipt and testing of raw materials, environmental monitoring and microbiology, analytical chemistry and QC compliance for the production of Phase 1, 2, 3 and commercial products manufactured from bacteria, yeast and mammalian cells. In this capacity, Dr Friedman enjoyed many client and regulatory interactions, both domestic and international. Prior to 2000, Dr. Friedman was the Laboratory Director for Chesapeake Biological Laboratories, a contract Aseptic Fill n' Finish manufacturer located in Baltimore, Maryland. In addition to the professional history listed above, other associations have included W.R. Grace, Sigma Chemical Co., Sherwood Medical, Becton Dickinson, American Cyanamid and Union Carbide. Dr. Friedman received his B.S. degree in Microbiology from Ohio State University, his M.S. from Michigan State University in Microbial Genetics, and his PhD from Ohio State University in Microbiology. For more information about this training visit https://www.researchandmarkets.com/r/w04u4w About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.